Characteristics of patients and controlsa
| . | Age (Years) . | Gender (M/F) . | Disease Duration (Years) . | CD4+CD28null T Cells (%) . | Anti-CMV IgG (U/ml) . | Medication . |
|---|---|---|---|---|---|---|
| HC1 | 30 | M | 5.3 | >250 | ||
| HC2 | 33 | M | 10.7 | 239.8 | ||
| HC3 | 30 | F | 9.4 | >250 | ||
| HC4 | 48 | M | 11.7 | >250 | ||
| RA1 | 76 | M | 19 | 6.5 | 219.9 | Colchicine |
| RA2 | 59 | F | 7 | 9.6 | >250 | Anti-TNFα, MTX |
| RA3 | 64 | F | 5 | 10.5 | >250 | MTX |
| RA4 | 71 | F | 16 | 11.8 | 113.6 | SSZ |
| MS1 | 39 | F | 10 | 7.4 | >250 | |
| MS2 | 50 | F | 2 | 8.1 | NA | Tyroxine |
| MS3 | 50 | F | 2 | 5.5 | NA | |
| MS4 | 51 | M | 9 | 5.7 | 243.6 |
| . | Age (Years) . | Gender (M/F) . | Disease Duration (Years) . | CD4+CD28null T Cells (%) . | Anti-CMV IgG (U/ml) . | Medication . |
|---|---|---|---|---|---|---|
| HC1 | 30 | M | 5.3 | >250 | ||
| HC2 | 33 | M | 10.7 | 239.8 | ||
| HC3 | 30 | F | 9.4 | >250 | ||
| HC4 | 48 | M | 11.7 | >250 | ||
| RA1 | 76 | M | 19 | 6.5 | 219.9 | Colchicine |
| RA2 | 59 | F | 7 | 9.6 | >250 | Anti-TNFα, MTX |
| RA3 | 64 | F | 5 | 10.5 | >250 | MTX |
| RA4 | 71 | F | 16 | 11.8 | 113.6 | SSZ |
| MS1 | 39 | F | 10 | 7.4 | >250 | |
| MS2 | 50 | F | 2 | 8.1 | NA | Tyroxine |
| MS3 | 50 | F | 2 | 5.5 | NA | |
| MS4 | 51 | M | 9 | 5.7 | 243.6 |
M, Male; F, female; %, percentage; NA, not analyzed; MTX, methotrexate; SSZ, sulfasalazine.